Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1485, doi. 10.1177/1352458515601513
- By:
- Publication type:
- Article
Works matching IS 13524585 AND DT 2015 AND VI 21 AND IP 12
Results: 16
1
2
Biotin and demyelinating diseases – a new connection?
- Published in:
- 2015
- By:
- Publication type:
- Opinion
3
Uniform guidelines for reporting COI within industry-sponsored clinical trials (ISCT).
- Published in:
- 2015
- By:
- Publication type:
- Opinion
4
Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1604, doi. 10.1177/1352458515596457
- By:
- Publication type:
- Article
5
Uhthoff questioned.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
6
Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1593, doi. 10.1177/1352458515569101
- By:
- Publication type:
- Article
7
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1600, doi. 10.1177/1352458514567728
- By:
- Publication type:
- Article
8
The influence of cognitive dysfunction on benefit from learning and memory rehabilitation in MS: A sub-analysis of the MEMREHAB trial.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1575, doi. 10.1177/1352458514567726
- By:
- Publication type:
- Article
9
Unilateral and bilateral upper limb dysfunction at body functions, activity and participation levels in people with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1566, doi. 10.1177/1352458514567553
- By:
- Publication type:
- Article
10
Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1533, doi. 10.1177/1352458514567215
- By:
- Publication type:
- Article
11
Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1513, doi. 10.1177/1352458514566666
- By:
- Publication type:
- Article
12
Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1557, doi. 10.1177/1352458514566417
- By:
- Publication type:
- Article
13
The high cost of spasticity in multiple sclerosis to individuals and society.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1583, doi. 10.1177/1352458514566416
- By:
- Publication type:
- Article
14
Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1546, doi. 10.1177/1352458514565959
- By:
- Publication type:
- Article
15
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1521, doi. 10.1177/1352458514564589
- By:
- Publication type:
- Article
16
Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 12, p. 1498, doi. 10.1177/1352458514566418
- By:
- Publication type:
- Article